Reneuron Share Discussion Threads

[algernon2] 14/7/2019 17:22

Afternoon Freddie?!
Sorry it took so long to reply.

[lauders] 13/7/2019 08:09

I also went back to see the BOD purchases since the capital reorganization took place at the beginning of January 2018.

27 Sept 2018 = Olav Hellebø, Chief Executive Officer - 14,936 @ 66.9p
27 Sept 2018 = Michael Hunt, Chief Financial Officer - 7,462 @ 67p
11 April 2019 = John Berriman, Non-executive Chairman - 80,000 @ 225p
11 April 2019 = Simon Cartmell OBE, NED - 7,758 @ 225.5516p
11 April 2019 = Professor Sir Chris Evans OBE, NED - 4,500 @ 221.5p
11 April 2019 = Dr Mike Owen, NED - 4,237 @ 236p
18 April 2019 = Professor Sir Chris Evans OBE, NED - 10,000 @ 228.7p

So highest price 236p and lowest 66.9p.

My only buy was around the average of Prof. Evans' purchases. I think that all the purchasers from 11th April on are expecting to benefit a lot more than they are now as the story unfolds. Sure hope so! Last time I did this was on the AMER BB and the BOD there invested a LOT more than the BOD here. In the meantime the share price there has declined pretty significantly despite the prospects, so over the short term BOD purchases don't necessarily mean a thing! Just wanted to post this as a reference for the BOD's "skin in the game" but some of them do have more than shown as they bought more in the years before.

Here is a list of total holdings per the 2018 annual report:

John Berriman - 10,434 (2018) 10,434 (2017)
Olav Hellebø - 6,694 (2018) 6,694 (2107)
Michael Hunt - 20,084 (2018) 20,084 (2017)
Simon Cartmell OBE - 7,875 (2018) 7,875 (2017)
Dr Tim Corn - 2,000 (2018) 2,000 (2017)
Dr Claudia D’Augusta 0 (2018) 0 (2017)
Professor Sir Chris Evans OBE - 240,105 (2018) 240,105 (2017)
Dr Mike Owen - 0 (2018) 0 (2017)

If Dr. Claudia buys any and Dr. Mike buys more we should all sit up and pay real attention!

Good to see there have been some buys (see first part) this year and towards the end of last year to change the numbers in the last list when released again in the 2019 annual report!

[lauders] 13/7/2019 06:26

Had a chance to listen to the Preliminary Results presentation and a little happier to keep the faith and wait for developments here.

(click on this link to register/log-in - )

On the hRPC front I was particularly pleased to hear (33.20 minutes/seconds in) that the RENE team are "not worrried about the duration of cell efficacy as they are new cells and are not diseased, but it is a matter of proving the point" and on the exosomes it would appear no deals will be made until Q4 from what was stated. hRPC is another matter! Again, another shareholding I have where patience (especially if Woodford decides to reduce more) is needed!

[manc10] 12/7/2019 10:22

raytard come out come out where ever you are down she goes

[small crow] 12/7/2019 08:02

Yes, positive sign that.

[lauders] 12/7/2019 08:00

With luck the RNS today will let us recover some of yesterday's sell-off. Not sure why they couldn't release both together yesterday? Anyway, looks a good appointment and certainly seems to strongly indicate that discussions on agreements are ongoing as stated yesterday and again today. Perhaps nearer than we think?

[rayrac] 11/7/2019 22:03

Well, up £9.2k at hur and had a third of it knocked off here...could have been worse!

[bigspuds] 11/7/2019 19:47

By Mark RobinsonWe haven't covered ReNeuron's(RENE) results since the end of 2016, but given the share price has risen by 148 per cent over the past 12 months, an assessment of recent events is in order. In February, the company announced "strongly positive preliminary efficacy data" in relation to clinical trials for its hRPC (human retinal progenitor cells) stem-cell therapy candidate in retinitis pigmentosa, a rare degenerative condition involving a breakdown and loss of cells in the retina.RENE:LSEReNeuron Group PLC1mthToday change-11.82%Price (GBP)242.50All three patients in the study showed "a rapid improvement in vision compared with their pre-treatment baseline". In practical terms, it meant the patients could read an additional four lines of letters on the standard ETDRS (early treatment diabetic retinopathy study) eye chart. Results for all the patients will be presented at the American Academy of Ophthalmology annual meeting in October. Management notes that "an improvement of at least 15 letters from baseline is considered to be clinically meaningful by the US Food and Drug Administration".RENEURON (RENE)   ORD PRICE:248pMARKET VALUE:£79mTOUCH:245-250p12-MONTH HIGH:333pLOW: 48pDIVIDEND YIELD:nilPE RATIO:naNET ASSET VALUE:74pNET DEBT:£26.4mYear to 31 MarTurnover (£000)Pre-tax profit (£m)Earnings per share (p)Dividend per share (p)2015 †30.0-10.3-50.0nil2016 †29.0-12.8-40.0nil2017 †46.0-18.2-49.2nil201843.0-21.0-55.7nil201949.0-17.2-45.2nil% change+14---Ex-div:-   Payment:-   †EPS for 2015-2017 adjusted to take account of capital reorganisationIC ViewReNeuron also commenced patient dosing in the US placebo-controlled Phase IIb clinical trial of its CTX stem-cell therapy candidate in chronic stroke disability, with top-line data from the study due in late 2020. The clinical progress hasn't gone unnoticed. Chinese drugs heavyweight Fosun Pharma has agreed to license the hRPC and CTX therapies as part of a deal worth up to £80m. Financials are of secondary importance as ReNeuron progresses its clinical programme, although N+1 Singer anticipates that cash will run out by March 2022, so it's probable that the gene therapy specialist will be tapping markets at some point.

[bigspuds] 11/7/2019 17:06

Hope no-one followed that INDVR tip this morning. If anyone did they would already be down 25%.......:(

[outsizeclothes.com] 11/7/2019 12:05

Woodford is still in the background, and is probably dumping, or trying to dump, into the rise of the last few days.
There's nothing here to trigger immediate "I have to buy this" interest from another biotech fund, and October is a long way off for a distressed seller.
Remember that Woodford HAS to get rid of 3.2% just to take the rest of his holding to a saleable 29.9%.
Unfortunate, as, prudently speaking, another funding round will be needed by the Company in 6 months time.
I'd also think that any biotech fund potentially then buying Woodford's 29.9% stake knows this, so would bargain hard. Remember that only 4 months ago we were at 70p !

[dickbush] 11/7/2019 11:09

I listened to the webcast and it seems that they are working on Fosun-style deals currently. A link-up with a US or European company could happen at any time. Like JBJ, I'm sticking with my holding in fear of Murphy's Law.

[supernumerary] 11/7/2019 10:23

PDT - the investigators have a lot to say in how the results are released - they will want to time it for release at their industry meeting so they can make a splash amongst their peers.

[manc10] 11/7/2019 09:53

anybody seen rayrac

[jensonbensonjohnson] 11/7/2019 09:48

Likewise. I dare say you could probably come out for a while and buy back in but I haven't got the stomach for that. Knowing my luck Johnson & Johnson would come in with a bid the moment I hit the sell button :)

[lauders] 11/7/2019 09:46

We may possibly see more BOD purchases if the weakness continues. I assume they are able to buy and it would be a positive sign. Shame that the strength did not continue today.

[pdt] 11/7/2019 09:42

A bit disappointing that there was no update, they have the 60 days results from the second cohort which they could have announced. However, I can also appreciate they don't want to drip feed information. It will be more substantial announcing in 3 months time at an event.

[alimo] 11/7/2019 09:40

ReNeuron to receive upfront, future near term and estimated success-based milestone payments of GBP80.0 million plus double-digit royalties on sales

Is this as good as it reads? If so why have we dropped a little this am?

[stewart_25] 11/7/2019 09:38

what relevance is the INDV news wooly? - sorry but not following them....

[dickbush] 11/7/2019 09:08

Quite right, small crow. I stand corrected.

[woolybadger62] 11/7/2019 09:07

Massive news at INDV guys £1.4 Billion payment Get in there